Silk Road Medical company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year




Total Raised


Date of IPO


Market Cap


Stock Price


About Silk Road Medical

Silk Road Medical develops and manufactures less-invasive medical devices intended to improve the treatment of carotid artery disease through proprietary transcarotid therapies. By focusing on proven surgical principles and developing technology for vascular specialists, the company can improve the lives of people with carotid artery disease.

Silk Road Medical Headquarter Location

735 Pastoria Ave

Sunnyvale, California, 94085,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Silk Road Medical

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Silk Road Medical is included in 2 Expert Collections, including Medical Devices.


Medical Devices

7,910 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Health IT

7,900 items

Silk Road Medical Patents

Silk Road Medical has filed 104 patents.

The 3 most popular patent topics include:

  • Vascular diseases
  • Arteries of the head and neck
  • Stroke
patents chart

Application Date

Grant Date


Related Topics




Arteries of the head and neck, Vascular diseases, Transcription factors, Interventional radiology, Medical equipment


Application Date


Grant Date



Related Topics

Arteries of the head and neck, Vascular diseases, Transcription factors, Interventional radiology, Medical equipment



Latest Silk Road Medical News

Silk Road Medical (SILK) Stock: Why The Price Grew 14.07% Today

May 3, 2022

The stock price of Silk Road Medical, Inc. (Nasdaq: SILK) increased by 14.07% today. This is why. The stock price of Silk Road Medical, Inc. (Nasdaq: SILK) – a company focused on reducing the risk of stroke and its devastating impact – increased by 14.07% today. Investors are responding positively to the company announcing that the U.S. Food and Drug Administration (FDA) approved expanded indications for the ENROUTE stent to include patients at standard risk for adverse events from carotid endarterectomy (CEA). Previously, the stent was approved for use only in patients with anatomic or physiological criteria that put them at high risk of complications from more invasive surgical procedures. Silk Road Medical had previously submitted a PMA supplement, which included data extracted from the Vascular Quality Initiative. And the surveillance data included in the submission represented real-world outcomes in 20,264 patients considered at standard surgical risk. Those data demonstrated that use of Silk Road Medical’s TCAR system is statistically non-inferior in stroke and death outcomes to CEA, while showing a ninefold reduction in cranial nerve injury (CNI) (2.7% vs 0.3%, p=<0.001). KEY QUOTES: “This is the first time in history that a stent-based approach has demonstrated non-inferiority in stroke and death rates relative to CEA, with our TCAR system offering the added benefit of significantly reduced cranial nerve injury risk. This label expansion levels a playing field once dominated by open surgical techniques, allowing an expanded number of patients and physicians access to the benefits of a less invasive treatment option.” – Erica Rogers, President and Chief Executive Officer of Silk Road Medical “Pairing the right patient with the right treatment results in significantly improved physician and patient experiences and outcomes. I speak for the vascular community in welcoming this label expansion for TCAR and recognizing this as a vital advancement in the treatment paradigm for patients at risk of stroke. The decision regarding which patients to treat with TCAR is no longer restricted to patients at high surgical risk, providing a greater opportunity for the care-team to pursue the less invasive approach for a broader set of their patients. At Beth Israel Deaconess, going forward, we expect that the right treatment for the majority of our atherosclerotic carotid disease patients will be TCAR.” – Dr. Marc L. Schermerhorn, Chief, Division of Vascular and Endovascular Surgery at Beth Israel Deaconess Medical Center Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.

Silk Road Medical Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Silk Road Medical Rank

You May Also Like


Quasar specializes in the manufacturing of products for the medical device market, and focuses on minimally invasive devices and disposables.


SMT develops and manufactures cardiac products in India. Its product portfolio includes coronary stents (drug-eluting and bare-metal), renal stents, angioplasty balloon catheters, and other cardiac accessories in India and abroad.

Translumina Logo

Translumina is a global Interventional cardiovascular devices company. Translumina is a fully integrated product development and manufacturing company with manufacturing facilities in Germany and India. The company commercializes products in over 50 countries globally through 2 distinct business entities, International and India.

Lepu Medical Logo
Lepu Medical

Lepu Medical (SHE:300003) is specialized in developing, manufacturing and marketing the high-tech medical devices and equipment.

Shanghai Kinetic

Shanghai Kinetic (300326.SZ) is a medical device manufacturer for multidisciplinary specialties including Orthopedics, Cardiovascular and Sports Medicine.

BridgePoint Medical Logo
BridgePoint Medical

BridgePoint Medical is focused on developing technology in the field of interventional cardiology for access to and treatment of chronic total occlusions.In September 2012, BridgePoint medical was acquired by Boston Scientific. The valuation of BridgePoint Medical was undisclosed. Other terms of the deal were not released.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.